Company Overview and News
PLANO, Texas, June 18, 2018 (GLOBE NEWSWIRE) -- Green Brick Partners, Inc. (NASDAQ:GRBK) (the “Company”) announced today that it is commencing a registered underwritten public offering of 10,700,000 shares of its common stock. The Company is issuing and selling 2,488,733 shares, and certain selling stockholders affiliated with Third Point LLC are selling 8,211,267 shares. The Company expects to grant the underwriters a 30-day option to purchase up to 1,605,000 additional shares of the Company’s common stock.
TABLE OF CONTENTS
PLANO, Texas, June 12, 2018 (GLOBE NEWSWIRE) -- Publicly traded diversified homebuilding and land development company, Green Brick Partners, Inc. (Nasdaq:GRBK) is excited to announce a newly developed affiliated business arrangement with PrimeLending (NMLS 13649).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Dan Loeb's 13F portfolio value decreased from $13.86B to $13.32B this quarter. The number of positions decreased from 44 to 40.
PCG ATHTF STZ.B TWX CVS CRM SHW GGAL HON AABA AVGO DOW DOV MELI MAC AET MMM PBF GD TPRE WP KDMN UTX STZ BKI TWC BABA DVMT GOOGL MSFT APY MHK QCOM GRBK MGM FB DOV.WI LEN NXPI PAM PE NFLX PF GOOG BAX LEN.B MPC PAGS ADBE SPGI RSPP VMC MON ICE SWN HON EA WYNN LYB FTI.WI FMC ANTM DWDP BID NEXA BLK XRAY T SUPV DHR ANTX
After nearly a decade of underperformance, big investors like Bill Ackman, George Soros, Carl Icahn, David Tepper, Larry Robbins, Leon Cooperman, Daniel Loeb, David Einhorn and Stanley Druckenmiller have managed to beat the broad market index this year. The group, often known as hedge funds and one that shifts composition from time to time, gained 0.39% through April as measured by the HFRI Fund Weighted Composite Index against the loss of 0.
SBIO FB TUSK NFLX ADBE XHS BRK.A IHF GOOGL AAPL MSFT FDN IGM GRBK
Investors have started mulling over the top bets of big investors like Bill Ackman, George Soros, Carl Icahn, David Tepper, Larry Robbins, Leon Cooperman, Daniel Loeb, David Einhorn and Stanley Druckenmiller, following the first-quarter release of 13F Forms. The group, often known as hedge funds and shifting composition, has outperformed the broad stock market this year after nearly a decade of underperformance.
SBBP FB TUSK PCRX TWX NFLX ZGNX TWC ADBE BRK.A RTRX GOOGL AAPL MSFT GHDX GRBK
David Einhorn’s Greenlight Capital added 2.1 million shares of Office Depot Inc (NASDAQ:ODP) and 212,500 shares of Abercrombie & Fitch Co. (NYSE:ANF) in the first quarter while also jettisoning some well-known names. With retail seemingly in a better place these days, does either Office Depot stock or ANF stock make sense in your portfolio?
ODP ANF GRBK
Green Brick Partners, Inc (NASDAQ:GRBK) Q1 2018 Earnings Conference Call May 8, 2018 12:00 PM ET
The following slide deck was published by Green Brick Partners, Inc in conjunction with their 2018 Q1 earnings call.
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Document TABLE OF CONTENTS
Basic EPS of $0.22 and Pre-Tax EPS of $0.29, up 69.2% and 38.1%; Pre-Tax Income of $14.5 million, up 44.6%; Revenue of $128.3 million, up 29.1%; Backlog of $226.5 million, up 56.0%
PLANO, Texas, May 03, 2018 (GLOBE NEWSWIRE) -- Green Brick Partners, Inc. (NASDAQ:GRBK) (the “Company” or “Green Brick”) announced that the Company will release its financial results for the first quarter ended March 31, 2018, after the market closes on Monday, May 7, 2018. Jim Brickman, Green Brick’s CEO, will host an earnings conference call to discuss its first quarter results at 12:00 p.m. Eastern Time on Tuesday, May 8, 2018.
Stay tuned for our coverage from Whitney Tilson’s conference this week. Tilson says that this is the first-ever conference dedicated entirely to shorting, The Art, Pain and Opportunity of Short Selling. Below readers can find a least of speakers and their bios – stay tuned for more\
SSREY GLRE DB JMPB JMPC JMPD MS.PRE MS.PRF MS.PRG NYTAB MS.PRA TNISY CRD TNISF MS.PRI MS.PRK CRDS TCM LNSTY MS GRBK JMP SSREF CRSS
7h - Asif
Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...
8h - Asif
Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
as of ET